GB0608483D0 - Biomarkers for endometrial proliferation - Google Patents

Biomarkers for endometrial proliferation

Info

Publication number
GB0608483D0
GB0608483D0 GBGB0608483.4A GB0608483A GB0608483D0 GB 0608483 D0 GB0608483 D0 GB 0608483D0 GB 0608483 A GB0608483 A GB 0608483A GB 0608483 D0 GB0608483 D0 GB 0608483D0
Authority
GB
United Kingdom
Prior art keywords
biomarkers
endometrial proliferation
endometrial
proliferation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0608483.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0608483.4A priority Critical patent/GB0608483D0/en
Publication of GB0608483D0 publication Critical patent/GB0608483D0/en
Priority to CA002648165A priority patent/CA2648165A1/en
Priority to MX2008013789A priority patent/MX2008013789A/es
Priority to JP2009506989A priority patent/JP2009535023A/ja
Priority to EP07724624A priority patent/EP2016417A1/en
Priority to BRPI0710912-1A priority patent/BRPI0710912A2/pt
Priority to CNA2007800144769A priority patent/CN101427139A/zh
Priority to KR1020087026231A priority patent/KR20090009212A/ko
Priority to AU2007247497A priority patent/AU2007247497A1/en
Priority to PCT/EP2007/003694 priority patent/WO2007128429A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57442—Specifically defined cancers of the uterus and endometrial
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
GBGB0608483.4A 2006-04-28 2006-04-28 Biomarkers for endometrial proliferation Ceased GB0608483D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB0608483.4A GB0608483D0 (en) 2006-04-28 2006-04-28 Biomarkers for endometrial proliferation
PCT/EP2007/003694 WO2007128429A1 (en) 2006-04-28 2007-04-26 Biomarkers for endometrial proliferation
EP07724624A EP2016417A1 (en) 2006-04-28 2007-04-26 Biomarkers for endometrial proliferation
MX2008013789A MX2008013789A (es) 2006-04-28 2007-04-26 Biomarcadores para proliferacion endometrial.
JP2009506989A JP2009535023A (ja) 2006-04-28 2007-04-26 子宮内膜増殖のバイオマーカー
CA002648165A CA2648165A1 (en) 2006-04-28 2007-04-26 Biomarkers for endometrial proliferation
BRPI0710912-1A BRPI0710912A2 (pt) 2006-04-28 2007-04-26 biomarcadores para proliferação endometrial
CNA2007800144769A CN101427139A (zh) 2006-04-28 2007-04-26 子宫内膜增殖的生物标记
KR1020087026231A KR20090009212A (ko) 2006-04-28 2007-04-26 자궁내막 증식에 대한 바이오마커
AU2007247497A AU2007247497A1 (en) 2006-04-28 2007-04-26 Biomarkers for endometrial proliferation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0608483.4A GB0608483D0 (en) 2006-04-28 2006-04-28 Biomarkers for endometrial proliferation

Publications (1)

Publication Number Publication Date
GB0608483D0 true GB0608483D0 (en) 2006-06-07

Family

ID=36590031

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0608483.4A Ceased GB0608483D0 (en) 2006-04-28 2006-04-28 Biomarkers for endometrial proliferation

Country Status (10)

Country Link
EP (1) EP2016417A1 (ja)
JP (1) JP2009535023A (ja)
KR (1) KR20090009212A (ja)
CN (1) CN101427139A (ja)
AU (1) AU2007247497A1 (ja)
BR (1) BRPI0710912A2 (ja)
CA (1) CA2648165A1 (ja)
GB (1) GB0608483D0 (ja)
MX (1) MX2008013789A (ja)
WO (1) WO2007128429A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2078728A1 (en) * 2008-01-14 2009-07-15 Université de Liège Novel isoform of versican and use in diagnosis and therapy
JP2024518180A (ja) * 2021-05-17 2024-04-25 エフ． ホフマン－ラ ロシュ アーゲー 腺筋症の非侵襲的診断のための血液バイオマーカーとしてのｓＦＲＰ４

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1159601A (en) * 1999-11-03 2001-05-14 Metris Therapeutics Limited Agents implicated in endometriosis
US20050214836A1 (en) * 2002-08-30 2005-09-29 Oncotherapy Science, Inc. Method of diagnosing ovarian endometriosis
WO2004056858A2 (en) * 2002-12-23 2004-07-08 Ingenium Pharmaceuticals Ag Methods and agents for diagnosis and prevention, amelioration or treatment of goblet cell-related disorders

Also Published As

Publication number Publication date
WO2007128429A1 (en) 2007-11-15
JP2009535023A (ja) 2009-10-01
EP2016417A1 (en) 2009-01-21
AU2007247497A1 (en) 2007-11-15
CA2648165A1 (en) 2007-11-15
BRPI0710912A2 (pt) 2012-02-22
CN101427139A (zh) 2009-05-06
MX2008013789A (es) 2008-11-14
KR20090009212A (ko) 2009-01-22

Similar Documents

Publication Publication Date Title
HK1134690A1 (zh) 子宮內膜生物標誌物
GB0625321D0 (en) Cancer biomarker
EP2089722A4 (en) BIOMARKERS
EP2162552A4 (en) BIOMARKERS FOR MELANOMES
EP2097094A4 (en) BIOMARKERS FOR NEUROLOGICAL SUFFERING
ZA200907027B (en) Biomarkers for multiple sclerosis
EP1910821A4 (en) BIOMARKER FOR OVARIAL CARCINOMA
GB0610828D0 (en) New use for cannabinoid
EP2265642A4 (en) BIOMARKERS
GB2436623B (en) Microtome
EP2095097A4 (en) XRF SYSTEM WITH DOUBLE SOURCE
EP2263086A4 (en) BIOMARKERS
GB0810709D0 (en) Biomarkers for lupus
GB0618127D0 (en) Biomarker
EP2210099A4 (en) BIOMARKER FOR OVARIAL CARCINOMA
GB0818660D0 (en) Biomarkers
GB0807214D0 (en) Biomarkers
GB0618429D0 (en) Cancer test
GB0511302D0 (en) Biomarkers
GB0612669D0 (en) Biomarkers for preeclampsia
EP2265641A4 (en) BIOMARKERS
GB0617212D0 (en) Techniques for endometrial ablation
GB0821912D0 (en) Biomarkers
GB0818658D0 (en) Biomarkers
GB0608483D0 (en) Biomarkers for endometrial proliferation

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)